9xchange Partners with PhaseV on Causal Machine Learning Clinical Trial Optimization

PhaseV, a leader in applying causal machine learning (ML) for dynamic clinical trial analysis and optimization, has formed a partnership with Israeli biopharma marketplace 9xchange. The collaboration integrates PhaseV’s ML technology into 9xchange’s transaction platform, providing its members the ability to retrospectively analyze and optimally design and execute advanced clinical studies.

Anat Naschitz, CEO and co-founder of 9xchange, stated, “Too many deserving drugs never get to patients due to insufficient resource or attention, or objective issues such as suboptimal trial design. The seamless, online and initially anonymous transaction path offered by 9xchange removes friction and unveils unexpected availability and matches, while enabling members to tap into new value through a range of AI/ML technologies. For our members, the PhaseV partnership means new opportunities. Owners can chart a new course for assets lost to trial failure, increase the value at sale and build confidence in a likely outcome. Buyers and investors can conduct due diligence on an asset and circumscribe the cost and probability of success. We build partnerships carefully, and are excited to collaborate with PhaseV, whose team and technology we find very impressive.”

PhaseV’s platform offers two key services in clinical trial optimization using Causal Machine Learning. The first service involves analyzing the impact of adaptive trial design and guiding optimal trial execution. The second offers advanced retrospective analysis to identify hidden signals in clinical data, aiding in the evaluation of endpoints and subpopulations for successful future trials. This approach has proven beneficial in drug repurposing and various therapeutic areas, including oncology, endocrinology, autoimmune diseases, and rare diseases.

“The latest advancements in causal inference and ML, when used right, enable us to harness available data to make informed and optimal decisions in the clinical development stage,” added Raviv Pryluk, CEO and co-founder of PhaseV. “One of the benefits of the 9xchange platform is that it helps liberate assets from owners who are unlikely to pursue them further, while providing access to the right technologies to unlock the potential of such assets and support the optimal trial to ensure their success.”

PhaseV recently raised $15 million in funding led by Viola Ventures and Exor Ventures. 9xchange also recently partnered with BenevolentAI, leveraging their technology for indication expansion and drug repurposing.

The post 9xchange Partners with PhaseV on Causal Machine Learning Clinical Trial Optimization appeared first on AIPressRoom.